Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients

Autores
Tetzlaff, Walter Francisco; Martín, Maximiliano Emmanuel; Botta, Eliana Elizabeth; Saez, María Soledad; Ferraro, Maria Florencia; Boero, Laura Estela; Sorroche, Patricia B; Arbelbide, Jorge; Brites, Fernando Daniel; Meroño, Tomás
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels wereobserved in patients with primary iron overload (IO).Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO after iron depletion.Materials and Methods:The study initially included 20 male patients with primary IO, defined by liver histology,from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months).Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship between changes in ferritin and in Lp-PLA2.Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, R2 = 0.60).Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied.
Fil: Tetzlaff, Walter Francisco. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Martín, Maximiliano Emmanuel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Botta, Eliana Elizabeth. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Saez, María Soledad. Hospital Italiano; Argentina
Fil: Ferraro, Maria Florencia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Boero, Laura Estela. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Sorroche, Patricia B. Hospital Italiano; Argentina
Fil: Arbelbide, Jorge. Hospital Italiano; Argentina
Fil: Brites, Fernando Daniel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Materia
IRON OVERLOAD
PHLEBOTOMY
LP-PLA2
HSCRP
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/134955
Acceder
id CONICETDig_532d1608bb7d87ca6a854246c729ec3e
oai_identifier_str oai:ri.conicet.gov.ar:11336/134955
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO PatientsTetzlaff, Walter FranciscoMartín, Maximiliano EmmanuelBotta, Eliana ElizabethSaez, María SoledadFerraro, Maria FlorenciaBoero, Laura EstelaSorroche, Patricia BArbelbide, JorgeBrites, Fernando DanielMeroño, TomásIRON OVERLOADPHLEBOTOMYLP-PLA2HSCRPhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels wereobserved in patients with primary iron overload (IO).Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO after iron depletion.Materials and Methods:The study initially included 20 male patients with primary IO, defined by liver histology,from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months).Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship between changes in ferritin and in Lp-PLA2.Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, R2 = 0.60).Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied.Fil: Tetzlaff, Walter Francisco. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Martín, Maximiliano Emmanuel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Botta, Eliana Elizabeth. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Saez, María Soledad. Hospital Italiano; ArgentinaFil: Ferraro, Maria Florencia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Boero, Laura Estela. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Sorroche, Patricia B. Hospital Italiano; ArgentinaFil: Arbelbide, Jorge. Hospital Italiano; ArgentinaFil: Brites, Fernando Daniel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaSryahwa Publications2019-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/134955Tetzlaff, Walter Francisco; Martín, Maximiliano Emmanuel; Botta, Eliana Elizabeth; Saez, María Soledad; Ferraro, Maria Florencia; et al.; Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients; Sryahwa Publications; Archives of Hematology and Blood Diseases; 2; 2-2019; 8-112639-3581CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.sryahwapublications.com/archives-of-hematology-and-blood-diseases/volume-2-issue-1info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:24:28Zoai:ri.conicet.gov.ar:11336/134955instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:24:28.467CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
title Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
spellingShingle Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
Tetzlaff, Walter Francisco
IRON OVERLOAD
PHLEBOTOMY
LP-PLA2
HSCRP
title_short Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
title_full Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
title_fullStr Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
title_full_unstemmed Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
title_sort Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients
dc.creator.none.fl_str_mv Tetzlaff, Walter Francisco
Martín, Maximiliano Emmanuel
Botta, Eliana Elizabeth
Saez, María Soledad
Ferraro, Maria Florencia
Boero, Laura Estela
Sorroche, Patricia B
Arbelbide, Jorge
Brites, Fernando Daniel
Meroño, Tomás
author Tetzlaff, Walter Francisco
author_facet Tetzlaff, Walter Francisco
Martín, Maximiliano Emmanuel
Botta, Eliana Elizabeth
Saez, María Soledad
Ferraro, Maria Florencia
Boero, Laura Estela
Sorroche, Patricia B
Arbelbide, Jorge
Brites, Fernando Daniel
Meroño, Tomás
author_role author
author2 Martín, Maximiliano Emmanuel
Botta, Eliana Elizabeth
Saez, María Soledad
Ferraro, Maria Florencia
Boero, Laura Estela
Sorroche, Patricia B
Arbelbide, Jorge
Brites, Fernando Daniel
Meroño, Tomás
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv IRON OVERLOAD
PHLEBOTOMY
LP-PLA2
HSCRP
topic IRON OVERLOAD
PHLEBOTOMY
LP-PLA2
HSCRP
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels wereobserved in patients with primary iron overload (IO).Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO after iron depletion.Materials and Methods:The study initially included 20 male patients with primary IO, defined by liver histology,from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months).Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship between changes in ferritin and in Lp-PLA2.Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, R2 = 0.60).Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied.
Fil: Tetzlaff, Walter Francisco. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Fisiopatología y Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Martín, Maximiliano Emmanuel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Botta, Eliana Elizabeth. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Saez, María Soledad. Hospital Italiano; Argentina
Fil: Ferraro, Maria Florencia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Boero, Laura Estela. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Sorroche, Patricia B. Hospital Italiano; Argentina
Fil: Arbelbide, Jorge. Hospital Italiano; Argentina
Fil: Brites, Fernando Daniel. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Meroño, Tomás. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
description Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory biomarker involved in atherosclerosis and cardiovascular disease (CVD). Iron stores may modify Lp-PLA2 as higher activity levels wereobserved in patients with primary iron overload (IO).Aim: to evaluate the changes of Lp-PLA2 activity and other atherosclerosis markers in patients with primary IO after iron depletion.Materials and Methods:The study initially included 20 male patients with primary IO, defined by liver histology,from which 7 were lost during follow-up and 13 completed the study (mean follow-up duration: 24±6 months).Phlebotomy treatment consisted in the removal of 1 unit of blood weekly or biweekly. We recorded traditional cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), and Lp-PLA2 activity. Longitudinal differences were tested by paired T or Wilcoxon tests. Linear regression was used to evaluate the relationship between changes in ferritin and in Lp-PLA2.Results: HFE mutations were present in 77% of the patients. Besides ferritin concentration (-74%), ALT (-11%) and Lp-PLA2 activities (-14%) were reduced after iron depletion (all p<0.05). Linear regression showed that changes in ferritin levels explained a 60% of the variability in the changes of Lp-PLA2 activity (B=0.80, p=0.008, R2 = 0.60).Conclusions: Treatment by phlebotomy significantly reduced the levels of Lp-PLA2 activity besides its expected effects in liver markers. The implications of iron depletion for the reduction of CVD risk remain to be studied.
publishDate 2019
dc.date.none.fl_str_mv 2019-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/134955
Tetzlaff, Walter Francisco; Martín, Maximiliano Emmanuel; Botta, Eliana Elizabeth; Saez, María Soledad; Ferraro, Maria Florencia; et al.; Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients; Sryahwa Publications; Archives of Hematology and Blood Diseases; 2; 2-2019; 8-11
2639-3581
CONICET Digital
CONICET
url http://hdl.handle.net/11336/134955
identifier_str_mv Tetzlaff, Walter Francisco; Martín, Maximiliano Emmanuel; Botta, Eliana Elizabeth; Saez, María Soledad; Ferraro, Maria Florencia; et al.; Lp-PLA2 Activity During Iron Depletion Treatment in Primary IO Patients; Sryahwa Publications; Archives of Hematology and Blood Diseases; 2; 2-2019; 8-11
2639-3581
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.sryahwapublications.com/archives-of-hematology-and-blood-diseases/volume-2-issue-1
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Sryahwa Publications
publisher.none.fl_str_mv Sryahwa Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614241474052096
score 13.070432

Publicaciones similares